A Phase 2, Multicenter, Randomized, Double-Blind, Controlled Study to Evaluate the Safety and Efficacy of Cortexolone 17α-Propionate (CB-03-01) Solution 5%, Minoxidil Solution 5%, and Vehicle Solution, Applied Twice-daily for 26 Weeks in Males With Androgenetic Alopecia (AGA)

Trial Profile

A Phase 2, Multicenter, Randomized, Double-Blind, Controlled Study to Evaluate the Safety and Efficacy of Cortexolone 17α-Propionate (CB-03-01) Solution 5%, Minoxidil Solution 5%, and Vehicle Solution, Applied Twice-daily for 26 Weeks in Males With Androgenetic Alopecia (AGA)

Completed
Phase of Trial: Phase II

Latest Information Update: 16 Mar 2017

At a glance

  • Drugs CB 03 01 (Primary) ; Minoxidil
  • Indications Alopecia
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Intrepid Therapeutics
  • Most Recent Events

    • 15 Jun 2016 Status changed from active, no longer recruiting to completed.
    • 10 Mar 2016 Planned End Date changed from 1 Jan 2016 to 1 Apr 2016 as reported by ClinicalTrials.gov record.
    • 12 Nov 2015 Planned End Date changed from 1 Nov 2015 to 1 Jan 2016 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top